A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Inclusion Criteria:
Exclusion Criteria:
CABA, 1023, Argentina
Capital Federal, C1120AAN, Argentina
Vancouver, British Columbia V5Z 1M9, Canada
Dresden, 01307, Germany
Homburg/Saar, 66424, Germany
Udine, Veneto 33100, Italy
Krakow, 31-501, Poland
Cheboksary, Mariy-El Republic 428000, Russia
Irkutsk, 664033, Russia
Novosibirsk, 630096, Russia
Ankara, 06490, Turkey (Türkiye)
Istanbul, 34421, Turkey (Türkiye)
Bristol, BS1 2LX, United Kingdom